Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.17 Average Target Price from Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have earned an average rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $62.1667.

Several analysts have issued reports on SUPN shares. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Frederick M. Hudson sold 5,369 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $50.61, for a total value of $271,725.09. Following the completion of the transaction, the director directly owned 60,413 shares of the company’s stock, valued at approximately $3,057,501.93. The trade was a 8.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jack A. Khattar sold 35,000 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $50.37, for a total transaction of $1,762,950.00. Following the completion of the transaction, the chief executive officer directly owned 958,100 shares of the company’s stock, valued at approximately $48,259,497. This represents a 3.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 120,881 shares of company stock worth $6,139,356 in the last 90 days. 8.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of SUPN. Hantz Financial Services Inc. raised its stake in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares in the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $49,000. EverSource Wealth Advisors LLC acquired a new stake in Supernus Pharmaceuticals in the second quarter worth $51,000. Finally, Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 268 shares during the period.

Supernus Pharmaceuticals Stock Down 2.2%

Shares of SUPN opened at $48.33 on Friday. The company’s fifty day moving average is $50.41 and its 200-day moving average is $49.84. Supernus Pharmaceuticals has a 12 month low of $30.83 and a 12 month high of $59.68. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -94.76, a price-to-earnings-growth ratio of 1.07 and a beta of 0.57.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.